EGFR and central nervous system cancer: Furthermore, the correlation of SLC32A1/MSR1 and C5AR1/SYT5 gene signatures with survival could potentially translate into clinical practice as a personalized protein or nucleic acid-based predictive tool which complements the actual work-up (EGFR amplification, TERT promoter mutation, chr 7 gain/chr 10 loss, and MGMT promoter methylation) in predicting aggressive behavior for IDH-WT infiltrating gliomas and would ensure better patient care.